Manufacturing Failures Place GMP Compliance in Spotlight - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Manufacturing Failures Place GMP Compliance in Spotlight
Fallout escalates from McNeil recall and Genzyme shortages as regulators review oversight.

Pharmaceutical Technology
Volume 34, Issue 8, pp. 26-30

Broader effects

Sharfstein used the Congressional hearing to "send the message" to manufacturers that FDA is significantly strengthening its oversight and criminal enforcement. Deborah Autor, director of compliance at the Center for Drug Evaluation and Research (CDER), said FDA's criminal investigative unit is examining whether J&J is criminally liable for McNeil's phantom recall and for the company's slow response to FDA inspection citations. Sharfstein added that FDA plans to consider corporate structure when enforcing the law, which would involve applying its experience at one facility to other operations run by the same company. Companies need strong compliance programs in place, he said, noting that FDA prefers to see industry adhere to the rules than to take enforcement action.

Manufacturers of older drug products in outdated facilities should take this advice seriously and modernize operations before difficulties arise. Quality control problems that emerged at Genzyme last year led to a plant shutdown, dangerous shortages in important treatments for rare diseases, and a contentious fight for control of the company. Genzyme CEO Henri Termeer almost lost his job and had to add new members to his board of directors in June to placate investor Carl Icahn. Genzyme had already been hit with FDA citations for GMP violations when the company discovered a virus in the bioreactors of its Allston Landing facility last year, just when it was trying to scale up production to meet growing demand for new and existing therapies. Additional fill-and-finish problems emerged later. The plant, which is more than 15 years old, had to close for several months to undergo a $9-million decontamination process.

In addition to losing millions in revenue, Genzyme also has to finance a $150-million program to renovate and bring the facility into compliance. Moreover, the company had to pay $175 million in fines for GMP violations and to accept an FDA consent decree that requires third-party monitoring of operations to ensure that new production complies with regulations. Potentially more damaging, FDA sped up its review and approval of competing therapies from two other firms to alleviate product shortages, a move that may limit Genzyme's ability to regain market share.

All signs point to continued FDA emphasis on speedy and efficient company responses to citations of product quality violations. In June, FDA's Center for Biologics Evaluation and Research (CBER) admonished Australian vaccine-maker CSL for failing to fully correct manufacturing deficiencies found during an April 2010 inspection. In an untitled letter, FDA cited inadequate testing of containers and closures as well as CSL's failure to investigate batch discrepancies or to establish testing procedures to ensure conformity to standards. Even though this FDA communiqué was not an official Warning Letter, Mary Malarkey, director of CBER's Office of Compliance and Biologics Quality, called for a meeting with CSL CEO Brian McNamee and his senior management to discuss how the company will develop a corrective action plan to address its violations and to ensure the production of safe, pure, and potent vaccines.

More authority

Although some members of Congress initially chastised FDA for failing to keep McNeil's adulterated children's medications off the market, the agency came out looking pretty tough from the May Oversight Committee hearing. FDA was able to document multiple efforts to compel McNeil compliance with quality standards, including frequent inspections of company facilities, numerous reports and Warning Letters, and the meeting with corporate executives when previous efforts failed to produce results.

Sharfstein also made the case for stronger FDA regulatory and recall authority. The J&J recall was voluntary because, under current policy, it's very difficult for FDA to compel a company to pull products from the market. Although most manufacturers comply with FDA recall requests, there is often is a lag between when the company becomes aware of adverse events and quality problems, and when that information reaches regulators. Several members of the House Committee indicated support for strengthening FDA's powers, as did Rep. Rosa DeLauro (D-CT), chair of the House Appropriations subcommittee that oversees FDA's annual budget. DeLauro sent a letter to Commissioner Hamburg complaining of McNeil's "reckless behavior" in disregarding GMPs at its facilities and in marketing inconsistent and noncompliant cold medications for children. The Congresswoman suggested that FDA might benefit from added authority to recall drugs and to require company monitoring of consumer complaints, and from more resources to conduct more frequent inspections.

The need for multiple inspections of J&J plants over the past few years has raised the issue of whether manufacturers that require repeat site audits should pay additional fees for the extra services. Reinspection user fees have been on FDA's wish list for several years as a way to boost revenue. Some policymakers have proposed that FDA collect fees for all field inspections as is done in Europe and many other countries. Such fees are not likely to be approved in the US, but asking violators to pay more for reinspections and secondary reviews may gain support.

One likely possibility is for FDA to require more extensive pharmaceutical company monitoring of suppliers and contract manufacturers. FDA holds the marketer of a finished drug responsible for ensuring that outside contractors comply with GMPs, but much of that oversight currently involves review of data and reports on quality-control systems and product attributes. Now, the agency is considering asking pharmaceutical companies to conduct on-site audits to confirm that contract manufacturers comply with rules and standards.

As these options are being debated, the legal issues exposed by FDA attorneys could have a broad impact on industry. Pharmaceutical companies are watching to see whether the agency brings criminal charges against J&J and McNeil, as well as enforcement action under its "responsible corporate officer" doctrine. The latter could involve individual misdemeanor charges, which can carry stiff fines and even prison terms.

Jill Wechsler is Pharmaceutical Technology's Washington editor, 7715 Rocton Ave., Chevy Chase, MD 20815, tel. 301.656.4634,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here